Abbas HA, Wierda WG. Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11:668162. https://doi.org/10.3389/fonc.2021.668162.

Google Scholar 

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474–84. https://doi.org/10.1093/eurheartj/ehab777.

Google Scholar 

Alu A, Lei H, Han X, Wei Y, Wei X. Btk inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15:138. https://doi.org/10.1186/s13045-022-01353-w.

Google Scholar 

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29. https://doi.org/10.1056/NEJMoa2025845.

Google Scholar 

Bui TT, Kim SH, Jung W, Yang SY, Tran QT, Lee H, et al. Pharmacokinetic and pharmacodynamic interaction of finerenone with diltiazem, fluconazole, and ritonavir in rats. Eur J Drug Metab Pharmacokinet. 2024;49:701–14. https://doi.org/10.1007/s13318-024-00917-0.

Google Scholar 

Chen B, Zhou D, Wei H, Yotvat M, Zhou L, Cheung J, et al. Acalabrutinib CYP3A-mediated drug-drug interactions: clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. Br J Clin Pharmacol. 2022;88:3716–29. https://doi.org/10.1111/bcp.15278.

Google Scholar 

Chen X, Hong F, Shen Y, Xia H, Shi L, Jiang Z, et al. Inhibitory effects of nimodipine, nitrendipine and felodipine on tamoxifen metabolism and molecular docking. Biochem Pharmacol. 2025;236:116854. https://doi.org/10.1016/j.bcp.2025.116854.

Google Scholar 

Cherng HJ, Jain N. First-line therapy for chronic lymphocytic leukemia: bruton tyrosine kinase or BCL2 or both? Hematol Oncol Clin North Am. 2021;35:725–38. https://doi.org/10.1016/j.hoc.2021.03.005.

Google Scholar 

Coates S, Lazarus P. Hydrocodone, oxycodone, and morphine metabolism and drug-drug interactions. J Pharmacol Exp Ther. 2023;387:150–69. https://doi.org/10.1124/jpet.123.001651.

Google Scholar 

da Cunha-Bang C, Niemann CU. Targeting Bruton’s tyrosine kinase across B-cell malignancies. Drugs. 2018;78:1653–63. https://doi.org/10.1007/s40265-018-1003-6.

Google Scholar 

Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, et al. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 2020. https://doi.org/10.3390/pharmaceutics12090846.

Google Scholar 

Gao N, Tian X, Fang Y, Zhou J, Zhang H, Wen Q, et al. Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. Eur J Pharm Sci. 2016;92:86–97. https://doi.org/10.1016/j.ejps.2016.06.015.

Google Scholar 

Gong EC, Chea S, Balupuri A, Kang NS, Chin YW, Choi YH. Enzyme kinetics and molecular docking studies on cytochrome 2B6, 2C19, 2E1, and 3A4 activities by sauchinone. Molecules. 2018. https://doi.org/10.3390/molecules23030555.

Google Scholar 

Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev. 2011;25:1–9. https://doi.org/10.1016/j.blre.2010.09.001.

Google Scholar 

Heinig R, Eissing T. The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone. Clin Pharmacokinet. 2023;62:1673–93. https://doi.org/10.1007/s40262-023-01312-9.

Google Scholar 

Knights KM, Stresser DM, Miners JO, Crespi CL. In vitro drug metabolism using liver microsomes. Curr Protoc Pharmacol. 2016;74:7.8.1-7.8.24. https://doi.org/10.1002/cpph.9.

Google Scholar 

Korzekwa K. Enzyme kinetics of oxidative metabolism-cytochromes P450. Methods Mol Biol. 2021;2342:237–56. https://doi.org/10.1007/978-1-0716-1554-6_9.

Google Scholar 

Lee J, Beers JL, Geffert RM, Jackson KD. A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment. Biomolecules. 2024. https://doi.org/10.3390/biom14010099.

Google Scholar 

Noe DA. Criteria for reporting noncompartmental estimates of half-life and area under the curve extrapolated to infinity. Pharm Stat. 2020;19:101–12. https://doi.org/10.1002/pst.1978.

Google Scholar 

Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20184331.

Google Scholar 

Podoll T, Pearson PG, Evarts J, Ingallinera T, Bibikova E, Sun H, et al. Bioavailability, biotransformation, and excretion of the covalent Bruton tyrosine kinase inhibitor Acalabrutinib in rats, dogs, and humans. Drug Metab Dispos. 2019;47:145–54. https://doi.org/10.1124/dmd.118.084459.

Google Scholar 

Qian Y, Wang X, Markowitz JS. In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites. Drug Metab Dispos. 2019;47:465–72. https://doi.org/10.1124/dmd.118.086074.

Google Scholar 

Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, et al. Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2023;5:570–90. https://doi.org/10.1016/j.jaccao.2023.09.002.

Google Scholar 

Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918–32. https://doi.org/10.1001/jama.2023.1946.

Google Scholar 

Surendran S, Paul D, Pokharkar S, Choulwar S, Deshpande A, Giri S, et al. Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: an application to pharmacokinetic study in Sprague Dawley rats. J Pharm Biomed Anal. 2019;164:509–13. https://doi.org/10.1016/j.jpba.2018.11.012.

Google Scholar 

Valluri VR, Katari NK, Khatri C, Kasar P, Polagani SR, Jonnalagadda SB. A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M(27) in human plasma and application to a human pharmacokinetic study. RSC Adv. 2022;12:6631–9. https://doi.org/10.1039/d1ra09026g.

Google Scholar 

Xu Y, Izumi R, Nguyen H, Kwan A, Kuo H, Madere J, et al. Evaluation of the pharmacokinetics and safety of a single dose of acalabrutinib in subjects with hepatic impairment. J Clin Pharmacol. 2022;62:812–22. https://doi.org/10.1002/jcph.2013.

Google Scholar 

Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007.

Google Scholar 

Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16:3480–675. https://doi.org/10.2174/092986709789057635.

Google Scholar 

Zhou D, Podoll T, Xu Y, Moorthy G, Vishwanathan K, Ware J, et al. Evaluation of the drug-drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach. CPT Pharmacometrics Syst Pharmacol. 2019;8:489–99. https://doi.org/10.1002/psp4.12408.

Google Scholar